Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
Evaluation of the Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
Sponsor: Ain Shams University
Listed as NCT02866214, this PHASE2/PHASE3 trial focuses on Endothelial Dysfunction and Endstage Renal Disease and remains completed. Sponsored by Ain Shams University, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jan 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ain Shams University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.